No abstract available.
Cell Line, Tumor* ; Doxorubicin* ; Epirubicin* ; Humans*

No abstract available.
Doxorubicin* ; Euonymus*

No abstract available.
Animals ; Doxorubicin* ; Rats*

No abstract available.
Cardiomyopathy, Dilated* ; Doxorubicin

No abstract available.
Doxorubicin* ; Etoposide* ; Stomach Neoplasms*

No abstract available.
Doxorubicin* ; Myocytes, Cardiac*

No abstract available.
Doxorubicin* ; Incidence* ; Stroke Volume*

Introduction: Doxorubicin (DOX) and paclitaxel (PTX) are both widely used anticancer drugs with a broad spectrum of antitumor activity, commonly against breast, ovarian, and lung cancers. Currently, these drugs are commercially available in liposomal formulations for their use in chemotherapy. This study generally proposed coconut oil bodies (COB) obtained from Cocos nucifera L. as an alternative carrier for DOX and PTX rather than the currently used liposome. Objectives: This study aimed to compare standard liposome and coconut oil bodies as drug carriers in terms of their microencapsulation efficiencies, lipid profiles, in vitro drug release and stability, as well as their cholesterol levels. Methods: Coconut oil bodies (COB) were isolated and purified from Cocos nucifera L. by modified sucrose gradient method followed by microencapsulation of standard drugs (doxorubicin and paclitaxel) through selfassembly and freeze-thaw method. The two standard drugs were encapsulated using COB and standard liposome. Encapsulation efficiency of both materials were determined. Lipid profiles of both encapsulating materials were analyzed by Fourier-transform infrared spectroscopy, gas chromatography-flame ionization detector, and cholesterol level determination. In vitro drug release and pH stability of both encapsulated drugs were analyzed. Results: Doxorubicin (DOX) and paclitaxel (PTX) were successfully incorporated in COB. Lauric acid was mainly abundant in COB and was able to lower cholesterol levels (5 mg/dL). COB incorporated with DOX and PTX showed stability at acidic and neutral pH. Drug release profile showed a rapid outburst within 3 hours compared to liposome encapsulated DOX and PTX. Conclusion Our study showed the encouraging potentials of using COB as wall materials that will make them attractive candidates for the formulation of pharmaceuticals for optimized drug delivery of cancer chemotherapeutics DOX and PTX
Liposomes ; Doxorubicin ; Paclitaxel

PURPOSE: Breast cancer ranks as the second most frequent cancer in women in Korea, and the rate is gradually increasing. Compared to European countries and USA., the Korean breast cancer occurs at a younger age (mean age: 47) than in western countries (mean age: 60). We suppose that there is some biological differences between Korean and western breast cancer. This study was designed to determine the target chemotherapy agents for use on individual patients and define target patients for chemotherapy during the post-op period. Additionally, we desired to acquire primary data for further proteomic analysis of patients. METHODS: Twenty-one patients with breast cancer were entered in this study. Tumor specimens were taken and informed consent was obtained for use of the samples in drug sensitivity testing. MTS[3-(4,5-dimethylthiazol-2-yl)-5- (3-carboxy methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] assay was able to be preformed in 16 patients (success rate, 76.2 percent). We used four drugs including Adriamycin, Epirubicin, 5-FU, and Taxol. RESULTS: In the axillary lymph node negative group, 5-FU (56.62%) and Taxol (53.85%) were sensitive drugs. There were no sensitive drugs in the p53 over-expression group. In the wild p53 group, 5-FU was the only sensitive drug. 5-FU was sensitive in both the ER and PR positive groups. Taxol was sensitive in the c-erbB2 low expression group. CONCLUSION: We obtained the results for chemosensitivity of breast cancer of Korean women. 5-FU and Taxol were relatively sensitive drugs, however we believe further data should be collected and added to obtain complete chemosensitivity results.
Breast Neoplasms* ; Breast* ; Doxorubicin ; Drug Therapy ; Epirubicin ; Female ; Fluorouracil ; Humans* ; Informed Consent ; Korea ; Lymph Nodes ; Paclitaxel

BACKGROUND: There has been a growing realization that a variety of anticancer drugs can induce apoptotic cell death. In the present study, an attempt was made to investigate the responsiveness of gastric cancer cells to various anticancer drugs and to identify which apoptosis-related proteins could be correlated to chemosensitivity. METHODS: Nine human Korean gastric cancer cell lines (SNU-1, -5, -16, -484, -601, -620, -638, -668, and -719) were analyzed. The cytotoxicity of each cell line to camptothecin, cisplatin, mitomycin C, vincristine, 5-FU, epirubicin, and doxorubicin was determined by using a MTT (dimethylthiazole- diphenyltetrazolium-bromide) assay. Apoptosis-related proteins (p53, p21, Bcl-2, Bcl-x, and Bax) were detected using a Western blot assay. RESULTS: Of the nine gastric cancer cell lines, SNU-1 was resistant while SNU-5 was sensitive to anticancer drugs. Mutated p53 was detected in all the cell lines. The highest expression of Bcl-2 was observed in SNU-1 while less or no expression of Bcl-2 was observed in SNU-5, -484, and -601. Bcl-xL was less expressed in SNU-5 than in the other cell lines. CONCLUSIONS: Chemosensitivity in gastric cancer cell lines was correlated mainly with the level of Bcl-2 and partly with that of Bcl-xL. There was no correlation between the chemosensitivity and other apoptosis-related proteins, such as p21, p53, Bax, and Bcl-xS in the studied gastric cancer cell lines.
Blotting, Western ; Camptothecin ; Cell Death ; Cell Line* ; Cisplatin ; Doxorubicin ; Epirubicin ; Fluorouracil ; Humans ; Mitomycin ; Stomach Neoplasms* ; Vincristine